Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theodore P Abraham

Showing results (151-160 of 157) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 157 results.
Journal of Cardiac Failure|March 17, 2024
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4Ahmad Masri, Mark V Sherrid, Theodore P Abraham, et al.
Circulation. Cardiovascular Imaging|January 12, 2019
Interobserver Variability in Applying American Society of Echocardiography/European Association of Cardiovascular Imaging 2016 Guidelines for Estimation of Left Ventricular Filling PressureSherif F Nagueh, Theodore P Abraham, Gerard P Aurigemma, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|July 5, 2015
A Summary of the American Society of Echocardiography Foundation Value-Based Healthcare: Summit 2014: The Role of Cardiovascular Ultrasound in the New ParadigmBenjamin F Byrd, Theodore P Abraham, Denis B Buxton, et al.
The New England Journal of Medicine|May 13, 2024
Aficamten for Symptomatic Obstructive Hypertrophic CardiomyopathyMartin S Maron, Ahmad Masri, Michael E Nassif, et al.
Journal of the American Heart Association|July 26, 2024
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMCaroline J Coats, Ahmad Masri, Michael E Nassif, et al.
Journal of the American College of Cardiology|October 1, 2024
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMMartin S Maron, Ahmad Masri, Michael E Nassif, et al.
JAMA|May 11, 2026
Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy: The NHLBI HCM Registry, Christopher M Kramer, Paul Kolm, et al.
Pageof 16

Showing results (151-160 of 157) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 157 results.
Journal of Cardiac Failure|March 17, 2024
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4Ahmad Masri, Mark V Sherrid, Theodore P Abraham, et al.
Circulation. Cardiovascular Imaging|January 12, 2019
Interobserver Variability in Applying American Society of Echocardiography/European Association of Cardiovascular Imaging 2016 Guidelines for Estimation of Left Ventricular Filling PressureSherif F Nagueh, Theodore P Abraham, Gerard P Aurigemma, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|July 5, 2015
A Summary of the American Society of Echocardiography Foundation Value-Based Healthcare: Summit 2014: The Role of Cardiovascular Ultrasound in the New ParadigmBenjamin F Byrd, Theodore P Abraham, Denis B Buxton, et al.
The New England Journal of Medicine|May 13, 2024
Aficamten for Symptomatic Obstructive Hypertrophic CardiomyopathyMartin S Maron, Ahmad Masri, Michael E Nassif, et al.
Journal of the American Heart Association|July 26, 2024
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMCaroline J Coats, Ahmad Masri, Michael E Nassif, et al.
Journal of the American College of Cardiology|October 1, 2024
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMMartin S Maron, Ahmad Masri, Michael E Nassif, et al.
JAMA|May 11, 2026
Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy: The NHLBI HCM Registry, Christopher M Kramer, Paul Kolm, et al.
Pageof 16